G2GBIO Inc
456160
Company Profile
Business description
G2GBIO Inc is a Biotechnology company. The company manages Drug Delivery System platform company. The company possesses microsphere source technology (InnoLAMP) for the development of sustained-release pharmaceuticals, and development a demand for extended-half-life drugs, as well as world-class mass production processes and facilities.
Contact
21 Medical Complex-gil
Osong-eup
Heungdeok-gu
Chungcheongbuk-do
Cheongju-si
KORT: +82 432706000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
48
Stocks News & Analysis
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
stocks
Fortescue costs outpace increasing volume
Higher diesel prices and foreign exchange hit unit cash costs.
stocks
A top global stock to buy after a big change in its forecast
Undervalued by 24%, this wide-moat stock is a buy now.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,268.50 | 10.00 | 0.11% |
| CAC 40 | 8,152.82 | 21.67 | 0.27% |
| DAX 40 | 24,894.44 | 38.64 | -0.15% |
| Dow JONES (US) | 48,967.47 | 444.93 | -0.90% |
| FTSE 100 | 10,207.80 | 58.95 | 0.58% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,841.20 | 239.85 | 1.02% |
| Nikkei 225 | 53,333.54 | 448.29 | 0.85% |
| NZX 50 Index | 13,510.88 | 50.14 | 0.37% |
| S&P 500 | 6,983.31 | 33.08 | 0.48% |
| S&P/ASX 200 | 8,941.60 | 14.90 | 0.17% |
| SSE Composite Index | 4,139.90 | 7.30 | 0.18% |